Midostaurin Capsules are indicated to treat aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia.
In 2023, total prescription medicine use increased by 3% and reached 210 billion days of therapy, per IQVIA's Use of Medicines in the U.S. 2024 report.